论文部分内容阅读
目的综合分析恩替卡韦联合阿德福韦酯治疗乙型肝炎肝硬化患者细菌感染诱发肝性脑病的临床治疗效果,为治疗乙型肝炎肝硬化感染患者提供数据参考。方法于2013年10月-2014年12月选择50例细菌感染诱发肝性脑病的乙型肝炎肝硬化患者临床资料,按照不同治疗方式,将其随机分为试验组与对照组,每组各25例;试验组患者应用恩替卡韦联合阿德福韦酯进行治疗,对照组患者应用阿德福韦酯进行治疗,统计分析两组患者白细胞(WBC)、总胆红素(TBIL)、谷丙转氨酶(ALT)水平以及病死率,数据采用SPSS 17.0统计软件进行分析。结果试验组患者病死率为40.0%、对照组为68.0%,两组病死率比较差异有统计学意义(P<0.05);两组患者治疗前WBC、TBIL、ALT水平比较,差异均无统计学意义;治疗后试验组的WBC、TBIL、ALT水平均低于对照组,差异有统计学意义(P<0.05)。结论恩替卡韦联合阿德福韦酯治疗乙型肝炎肝硬化患者细菌感染诱发肝性脑病的临床治疗效果较理想。
Objective To comprehensively analyze the clinical effect of entecavir and adefovir dipivoxil in the treatment of hepatic encephalopathy induced by bacterial infection in patients with hepatitis B cirrhosis and provide data reference for the treatment of patients with hepatitis B cirrhosis. Methods From October 2013 to December 2014, 50 patients with hepatitis B cirrhosis induced by bacterial infection were selected. According to the different treatment methods, they were randomly divided into experimental group and control group with 25 Patients in the test group were treated with entecavir and adefovir dipivoxil, while those in the control group were treated with adefovir dipivoxil. The levels of leukocyte (WBC), total bilirubin (TBIL) and alanine aminotransferase ALT) and mortality, the data using SPSS 17.0 statistical software for analysis. Results The case fatality rate was 40.0% in the trial group and 68.0% in the control group, with significant differences in the case fatality rate (P <0.05). There was no significant difference in WBC, TBIL and ALT between the two groups before treatment Significance; WBC, TBIL, ALT levels of the experimental group after treatment were lower than the control group, the difference was statistically significant (P <0.05). Conclusion Entecavir combined with adefovir dipivoxil treatment of hepatitis B cirrhosis patients with bacterial infection induced hepatic encephalopathy clinical effect is more satisfactory.